Treatment for neoplastic diseases
Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects.
1. A method of stabilizing a progressive cancer in a human patient having cancer that has progressed after treatment with chemotherapy, radiotherapy, or biologic agents, the method comprising the step of repeatedly administering to the human patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-interleukin-1alpha (anti-IL-1α) antibody at least until the progression of the cancer has been stabilized, wherein the anti-IL-1α antibody binds human IL-1α with a Ka of at least 1×10 9 M −1 .
2. The method of claim 1 , wherein the human patient's progressive cancer is metastatic, and the step of repeatedly administering the pharmaceutical composition results in a decrease in the tumor burden in the patient.
3. The method of claim 1 , wherein the progressive cancer is metastatic colorectal cancer.
4. The method of claim 2 , wherein the progressive cancer is metastatic colorectal cancer.
5. The method of claim 1 , wherein the progressive cancer is metastatic non-small cell lung cancer.
6. The method of claim 2 , wherein the progressive cancer is metastatic non-small cell lung cancer.
7. The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody (mAb).
8. The method of claim 7 , wherein the mAb is an IgG1.
9. A method of stabilizing a progressive cancer in a human patient having cancer that has progressed after treatment with chemotherapy, radiotherapy, or biologic agents, the method comprising the step of repeatedly administering to the human patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-interleukin-1alpha (anti-IL-1α) antibody at least until the progression of the cancer has been stabilized, wherein the anti-IL-1α antibody is not conjugated to a radionuclide, and wherein the anti-IL-1α antibody is an IgG1 and binds human IL-1α with a Ka of at least 1×10 9 M + 1.
10. The method of claim 9 , wherein the human patient's progressive cancer is metastatic, and the step of repeatedly administering the pharmaceutical composition results in a decrease in the tumor burden in the patient.
11. The method of claim 9 , wherein the progressive cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer, metastatic colorectal cancer, and metastatic non-small cell lung cancer.
12. The method of claim 9 , wherein the anti-IL-1α antibody is a monoclonal antibody (mAb).